Treatment of anxiety-related insomnia with chlormezanone.
Twenty-nine patients seen in general practice suffering from sleep disturbance due to mild neurotic anxiety were treated with 400 mg chlormezanone per night for 2 weeks. Patients' and doctors' assessments of quality of sleep and Hamilton anxiety rating scores were carried out initially and after 1 and 2 weeks. Patients also completed a daily record card assessing their sleep. The results suggest that chlormezanone produced prompt improvement within 2 nights of the start of treatment, and by the end of the study period only 2 (7%) patients still reported their sleep as being poor compared with 80% initially, and 19 (66%) rated their sleep as good or excellent. There was a steady reduction in anxiety rating scores throughout treatment. Only 1 patient reported a transient mild side-effect.
D000328:Adult; D000368:Aged; D001007:Anxiety / Q000150:complications*; D002720:Chlormezanone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012890:Sleep / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors
D002720:Chlormezanone